{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "timestamp": "2023-07",
        "content": "Patient presented with left abdominal pain for 1 month. Diagnosed with pulmonary enteric adenocarcinoma (PEAC). PEAC pathological features showed enteric origin or enteric morphology similar to lung metastatic colorectal cancer (lmCRC). Diagnostic criteria include colorectal morphologic cells exceeding 50% of the tumor tissue and positive for at least one colorectal immunophenotype, including CDX-2, CK20, SATB2, and MUC2, Villin, clinically excluding colorectal cancer.",
        "clinical_data": {
          "HPI": [
            {
              "summary": "Patient presented with left abdominal pain for 1 month.",
              "duration": "P1M",
              "onset": null,
              "progression": "unknown",
              "associated_symptoms": [
                "Left abdominal pain"
              ],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ],
          "diagnoses": [
            {
              "code": "C4082422",
              "label": "pulmonary enteric adenocarcinoma",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C0009402",
              "label": "Colorectal Cancer",
              "status": "suspected",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "PET-CT showed soft tissue lesions in the left upper lobe of the lung with increased FDG metabolism, suggesting possible lung cancer. Left hilar lymph node was enlarged. Soft tissue density shadows in bilateral adrenal glands and left kidney posteromedial were considered as metastases.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Lesion (finding)",
              "body_part": "Left upper lobe of lung",
              "modality": "PET-CT",
              "finding": "Soft tissue lesions with increased FDG metabolism",
              "impression": "Possible lung cancer",
              "date": null
            },
            {
              "type": "Lymph node enlargement",
              "body_part": "Left hilar lymph node",
              "modality": "PET-CT",
              "finding": "Enlarged",
              "impression": null,
              "date": null
            },
            {
              "type": "Soft tissue density shadows",
              "body_part": "Bilateral adrenal glands",
              "modality": "PET-CT",
              "finding": "Soft tissue density shadows",
              "impression": "Metastases",
              "date": null
            },
            {
              "type": "Soft tissue density shadows",
              "body_part": "Left kidney posteromedial",
              "modality": "PET-CT",
              "finding": "Soft tissue density shadows",
              "impression": "Metastases",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "CT-guided biopsy of the left lung lesion was performed.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Biopsy",
              "approach": "percutaneous",
              "location": "Left lung",
              "modality": "CT"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Pathology results suggested adenocarcinoma with poor expression of pulmonary markers. Immunohistochemistry (IHC): TTF-1 (-), CK7 (+), Napsin A (-), CEA (+), CK5/6 (+), Syn (-), P63 (-), Ki-67+ (50%). Genetic test results: KRAS mutation abundance of 31.22%, no EGFR, AKL, ROS-1, MET, HER-2 mutations found. PD-L1 expression status was unknown.",
        "clinical_data": {
          "labs": [
            {
              "test": "Immunohistochemistry",
              "value": "TTF-1 (-), CK7 (+), Napsin A (-), CEA (+), CK5/6 (+), Syn (-), P63 (-), Ki-67+ (50%)",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "KRAS mutation abundance",
              "value": "31.22%",
              "unit": "%",
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "EGFR mutation",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "ALK mutation",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "ROS-1 mutation",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "MET mutation",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "HER-2 mutations",
              "value": "negative",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "PD-L1 expression status",
              "value": "unknown",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": "C400633",
              "label": "Adenocarcinoma",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "timestamp": "2023-08-19",
        "content": "Clinical stage IV. Received first cycle of immune checkpoint inhibitor (ICI) plus platinum-based chemotherapy: Tislelizumab 200mg d1+ pemetrexed 500mg/m2 d1+ cisplatin 75mg/m2 d2, every 3 weeks.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0008893",
              "dosage": "200mg",
              "frequency": "d1",
              "modality": "IV",
              "start_date": null,
              "end_date": null
            },
            {
              "drug": "C0677858",
              "dosage": "500mg/m2",
              "frequency": "d1",
              "modality": "IV",
              "start_date": null,
              "end_date": null
            },
            {
              "drug": "C0008829",
              "dosage": "75mg/m2",
              "frequency": "d2",
              "modality": "IV",
              "start_date": null,
              "end_date": null
            }
          ],
          "diagnoses": [
            {
              "code": "C1517268",
              "label": "Stage IV",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Progression of pulmonary enteric adenocarcinoma (PEAC) with suspected lung cancer and metastases.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0000729"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Diagnostic biopsy performed to evaluate lung lesion.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C0005594"
          ],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Pathology and genetic testing results obtained from lung lesion biopsy.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0030705",
            "C0022659"
          ],
          "change_type": "addition",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Patient initiated on first cycle of immune checkpoint inhibitor (ICI) plus platinum-based chemotherapy.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0008893",
            "C0677858",
            "C0008829"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2023-08-19T00:00:00Z"
        }
      }
    }
  ]
}